CYP2C19*2 & *3 Detection Kit (RUO)

Drug & Gene Information:

Relating to Drug: Clopidogrel (Brand name: Plavix)

Clodpgrel, an antiplatelet agents is indicated for the reduction of thrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease. For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.

CYP2C19*2 & *3 Detection Kit (RUO)

CYP2C19*2 & *3 Detection Kit (RUO)

Pharmacokinetic and antiplatelet tests of the active metabolite of Clopidogrel show that the drug levels and antiplatelet effects differ depending on the genotype of the CYP2C19 enzyme.

The following represent the different alleles of CYP2C19 that make up a patient's genotype:

The CYP2C19*1 allele has fully functional metabolism of Clopidogrel

The CYP2C19*2 and *3 alleles have no functional metabolism of Clopidogrel. These two alleles account for most of the reduced function alleles in patients of Caucasian (85%) and Asian (99%) descent classified as poor metabolizers.

In March 2010, the US FDA put a black box warning on Plavix to make patients and healthcare providers aware that CYP2C19 poor metabolizers, representing up to 14% of patients, are at high risk of treatment failure and that testing is available.